Kiora Pharmaceuticals (KPRX) EBITDA (2016 - 2026)

Kiora Pharmaceuticals (KPRX) has reported EBITDA for 11 consecutive years, with -$2.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA rose 7.61% year-over-year to -$2.2 million; the trailing twelve-month figure through Jun 2026 stood at -$12.8 million (down 17.76% YoY), and the FY2025 full-year result was -$12.8 million, down 384.48% from the prior year.
• EBITDA climbed to -$2.2 million in Q2 2026 per KPRX's latest filing, from -$2.5 million in the prior quarter.
• Across five years, EBITDA topped out at $13.2 million in Q1 2024 and bottomed at -$7.3 million in Q4 2025.
• Historically, EBITDA has averaged -$2.1 million across 5 years, with a median of -$2.5 million in 2024.
• The sharpest annual moves came in 2024 and 2025: EBITDA surged 789.85% in 2024, then plunged 185.03% in 2025.
• Over 5 years, EBITDA stood at -$2.6 million in 2022, then gained by 19.6% to -$2.1 million in 2023, then declined by 21.05% to -$2.6 million in 2024, then slumped by 185.03% to -$7.3 million in 2025, then jumped by 69.72% to -$2.2 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$2.2 million, -$2.5 million, and -$7.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.